Launching of the New Comprehensive Stroke & Neurology Clinic in the Greater Toronto Area (GTA) – ABOUT INSIDER

HELLO DR. ATIF ZAFAR! THANKS FOR TAKING THE TIME TO CHAT WITH US! TELL US A BIT ABOUT STROKE CARE IN CANADA IN GENERAL AND TORONTO IN PARTICULAR?In Canada, stroke occurs every 9 minutes. Believe it or not, we lose two million neurons every single minute we wait out before seeking care. Imagine if all stroke patients can make to the hospital as soon as the stroke strikes, the world will be a better place. Ontario, being the most populated province in the country is impacted by stroke the most. In GTA (Greater Toronto Area), there are various stroke centers spread across the territory. A few of those hospitals are comprehensive centers where both medical and surgical treatment of stroke care is available. An area of concern is the lack of access to stroke specialists for patients at risk of having future stroke.

WHY DID YOU MOVE TO TORONTO, CANADA FROM THE US?I am passionate about building health systems and programs in states, provinces and seeing the public health impact at the national level. My previous experience in the US includes starting a stroke program from scratch and eventually transforming it into a comprehensive academic stroke leader in the region. When I heard about the opportunity at St. Michaels Hospital/Unity Health, an academic hospital of the University of Toronto, I felt I can make a difference in how we manage stroke care in the region. I am also very interested in understanding the 2 different healthcare systems in North America the US and Canada boast two different models of healthcare and as a physician and student of leadership, I am curious to see how an amalgamation of these 2 models may create an innovative modern hybrid healthcare system that may be sustainable, dynamic and patient-centric.

WHAT IS YOUR MESSAGE TO OTHER PHYSICIANS, FAMILY DOCTORS IN THE GTA?I have spoken with various partners in the GTA area and realized that access for neurologists and stroke doctors in an issue for our colleagues in family medicine and other specialties. As the medical director of stroke program at St. Michaels Hospital, I am prioritizing patient access to neurologist as the main issue. We are providing rapid access to stroke and cerebrovascular patients in our stroke clinic with option to be seen in person or via tele-health. You can connect visit atifzafar.com for more information.

WHAT IS YOUR MESSAGE TO YOUR PATIENTS IN TORONTO AND IN CANADA?Dont wait it out, when you are having stroke symptoms. Also, if you have risk factors like hypertension, diabetes, cholesterol problems, obstructive sleep apnea, or other similar risk factors, make sure you stay on top of it. If you dont, you may be at higher risk of having a stroke or heart attack. Also, we have a Stroke Clinic located at St. Michaels Hospital, 30 Bond Street, Toronto, Ontario where you are more than welcome to come and talk to me or any of my partners who specialize in stroke and cerebrovascular diseases. In the times of COVID19, we also offer tele-clinics where you can get access to care through online or phone communications. You can visit atifzafar.com for more information or visit St. Michaels Hospital Stroke website.

Follow this link:
Launching of the New Comprehensive Stroke & Neurology Clinic in the Greater Toronto Area (GTA) - ABOUT INSIDER

Neurology Devices Market is Expected to Thrive at Impressive CAGR by 2025 – TechnoWeekly

Neurology Devices MarketInsights 2020 is an expert and top to bottom investigation on the momentum condition of the worldwide Neurology Devices industry with an attention on the Global market. The report gives key insights available status of the Neurology Devices producers and is an important wellspring of direction and course for organizations and people keen on the business. By and large, the report gives an inside and out understanding of 2020-2025 worldwide Neurology Devices market covering extremely significant parameters.

Request Free Sample copy of this report athttps://www.precisionbusinessinsights.com/request-sample?product_id=36981&utm_source=daily&utm_medium=24

Key Players in Neurology Devices Market areJohnson & Johnson (U.S.),MicroPort Scientific Corporation (China),Medtronic plc (Ireland),Penumbra, Inc. (U.S.),Terumo Corporation (Japan),Merit Medical Systems, Inc. (U.S.),Abbott Laboratories (U.S.),L. Gore & Associates, Inc. (U.S.).

Regions Covered in the Neurology Devices Market:

Global Neurology Devices Market report is a comprehensive study of the global market and has been recently added by PrecisionBusinessInsights to its extensive database. Augmented demand for the global market has been increased in the last few years. This informative research report has been scrutinized by using primary and secondary research. The Global Neurology Devices Market is a valuable source of reliable data including data of the current market.

Request Free Customization copy of this report athttps://www.precisionbusinessinsights.com/request-customisation?product_id=36981&utm_source=daily&utm_medium=24

This research report represents a 360-degree overview of the competitive landscape of the Global Neurology Devices Market. Furthermore, it offers massive data relating to recent trends, technological, advancements, tools, and methodologies. The research report analyzes the Global Neurology Devices Market in a detailed and concise manner for better insights into the businesses.

The research study has taken the help of graphical presentation techniques such as infographics, charts, tables, and pictures. It provides guidelines for both established players and new entrants in the Global Neurology Devices Market.

The detailed elaboration of the Global Neurology Devices Market has been provided by applying industry analysis techniques such as SWOT and Porters five-technique. Collectively, this research report offers a reliable evaluation of the global market to present the overall framework of businesses.

Key Features of the Report:

The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis in addition to recent technology advancements and innovations in the market.

What is the Impact of Covid-19 Outbreak on the Neurology Devices?

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our team is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us:

[emailprotected]

PH +1-866-598-1553

More here:
Neurology Devices Market is Expected to Thrive at Impressive CAGR by 2025 - TechnoWeekly

Rare Neurological Disease Treatment Market: Growing prevalence of rare neurological diseases across the globe to drive the market – BioSpace

Global Rare Neurological Disease Treatment Market Overview

Rare neurological diseases are vastly underdiagnosed and most of them go untreated. Additionally, until recently there has been no specific treatments for such disorders. However, the landscape of the market is changing slowly. It is expected that the global rare neurological disease treatment market will have a great potential in the coming years of the forecast period ranging from 2020 to 2030. Increasing awareness about these diseases, advancing healthcare and neurobiological technologies, and fast track approvals of new treatment methods are some of the key factors that will help in pushing up the growth of the global market.

Read Report Overview - https://www.transparencymarketresearch.com/rare-neurological-disease-treatment-market.html

Global Rare Neurological Disease Treatment Market Notable Developments

In terms of competitive landscape of the global neurological disease treatment market, there are several key players operating in the market space. This makes the competitive landscape a highly fragmented one. The companies in the market are mainly focusing on developing new and innovative therapeutics to diagnose and treat these neurological diseases. The market consists of a few significant players who dominate the market. Some of the leading market players include CSL Ltd, Kedrion Biopharma Inc., US WorldMeds LLC (Solstice Neurosciences LLC), Merz Pharma GmbH & Co. KGaA, Aquestive Therapeutics Inc., Bayer AG, Pfizer Inc., Novartis AG, Merck & Co. Inc. (EMD Serono Inc.), and Jazz Pharmaceuticals PLC.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79898

Global Rare Neurological Disease Treatment Market Driver and Restraints

There are several factors that are responsible for the overall development of the global rare neurological disease treatment market. One of the key driving factor for the growth of the global market has been the increasing activities of research and development to find cures for such disorders. In recent years, there has been a growing prevalence of rare neurological diseases across the globe. Most of them go unnoticed or are underdiagnosed. A lack of effective treatment is the most prominent driving factor for the key players in the market that will help it grow in the coming years of the forecast period. Another important factor for the growth of the market is growth focus on fast-track approvals for new and upcoming therapies to treat such disorders. Furthermore, recent technological advancements in the field of neurology and neuro-biology has also fueled the development of the global neurological disease treatment market. Also, increasing awareness about early diagnosis of these disorders might help the market growth in coming years.

Request for Analysis of COVID-19 Impact on Rare Neurological Disease Treatment Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79898

One key restraining factor for the growth of the global neurological disease treatment market has been lack of standard treatment to cure these disorders.

Global Rare Neurological Disease Treatment Market Geographical Outlook

Based on the geographical segmentation, the global rare neurological disease treatment market is divided into five key regions. These regions are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Of these currently, the global neurological disease treatment market is expected to be dominated by the regional segment of North America. The region is expected to account for a larger chunk of the global market in coming years of the forecast period ranging from 2020 to 2030. One of the key reasons of the growth of the North America market has been the increasing prevalence of such rare neurological diseases across the region. According to the Center for Rare Neurological Disease Research report, rare neurological diseases have an impact on around 200,000 individuals in the US alone. In addition to this, growing healthcare spending and availability of a matured and well-established nature of healthcare infrastructure is expected to fuel the development of the North America region.

Pre Book Rare Neurological Disease Treatment Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=79898&ltype=S

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Continue reading here:
Rare Neurological Disease Treatment Market: Growing prevalence of rare neurological diseases across the globe to drive the market - BioSpace

Direct Imaging May Localize Seizure Onset Zone in Patients With Focal Epilepsy – Neurology Advisor

Direct imaging with high-density electroencephalography (EEG) may localize seizure onset zone prior to surgery in patients with focal epilepsy, according to study results published in Neurology.

Identifying the epileptogenic zone is crucial prior to surgical intervention for focal epilepsy and in recent years, EEG has become an important modality to guide surgical interventions. The objective of the current study was to assess the role of EEG recordings and source localization analyses in localizing seizure onset zone prior to surgical planning in patients with focal epilepsy.

The study included 39 adult patients (51.28% women; mean age, 17.87 years) with partial seizures who underwent pre-surgical evaluation with high-density long-term EEG monitoring at Mayo Clinic, Rochester, MN, between 2007 and 2017. Patients underwent either surgical resection or invasive intracranial EEG monitoring. Study researchers used a new method for directly imaging seizure sources and interictal spikes from high density EEGs, and confirmed it for seizure onset zone localization assessed with intracranial EEG findings and surgical resection volume.

There were a total of 138 seizures included in the study. The sub-lobar concordance rate between EEG seizure onset zone results and clinical findings was 94.87%. The difference was more significant in patients with greater than 1 interictal epileptic discharge cluster as ictal source imaging indicated a concordance rate of 87.5%.

The mean localization error, calculated as the average distance from the estimated source to the closest intracranial seizure onset zone electrode, was about 1.35 cm in patients with concordant results. For patients following successful surgery, the average distance from the estimated source to the boundary of the resected volume was 0.74 cm.

The interictal study included at least 10 hours of recordings for each patient. The concordance rate was 78.4% when study researchers used the dominant interictal epileptic discharge cluster for source imaging. The difference was more significant in patients with greater than 1 interictal epileptic discharge cluster as the interictal source imaging showed a concordance rate of 56.2%.

The study had several limitations, including limiting participants to patients with focal epilepsy, the use of high quality magnetic resonance imaging, and the use of high-density EEG.

The present study demonstrates the clinical applicability and merits of a noninvasive electrophysiological seizure imaging approach, which is currently missing in clinical routine, but may become an important component of the pre-surgical evaluation routine for epilepsy treatment, concluded the study researchers.

Reference

Ye S, Yang L, Lu Y, et al. Contribution of ictal source imaging for localizing seizure onset zone in patients with focal epilepsy patients. Neurology. Published online October 23, 2020. doi:10.1212/WNL.0000000000011109

Read the original post:
Direct Imaging May Localize Seizure Onset Zone in Patients With Focal Epilepsy - Neurology Advisor

Clubs may need to hire neurologists as part of plans to combat concussion – The Guardian

Football clubs may be required to add neurologists to their medical teams as part of plans to confront concussion in the sport.

Trials of concussion substitutes are expected to be authorised by the games rule-making body, Ifab, next month as the authorities attempt to get to grips with the risk of brain injuries.

But the complexities of implementing a plan, including the possible recruitment of extra medical staff and the logistical and legal challenges around the trials, may mean they are not implemented until the 2021-22 season.

The recent diagnosis of dementia in Sir Bobby Charlton, the death of Nobby Stiles and campaigning by families of former players with dementia have returned focus to the risks of neurodegenerative disease.

On Wednesday the Professional Footballers Association announced it would launch a working group including relatives of former players to help refine its support provisions for former players with neurodegenerative conditions.

There remains great uncertainty over how to best limit the risk in contemporary generations of players, however. Action was taken this year in England, Scotland and Northern Ireland to ban heading in training for under-12s, with some limitations for older children too.

But adults face no limitations on heading practice, with Gary Lineker coming out in favour of restrictions. Theres absolutely no reason to head the ball in training, the former England striker tweeted.

Players face further risks during matches and in December Ifab plans to confirm a protocol that would allow teams extra substitutes in the event of an apparent concussion. If the protocol is approved at Ifabs annual business meeting, competitions will be invited to apply to trial the protocols with campaigners hoping these could begin this season.

Under the protocol, club doctors would have three minutes to evaluate a player on the field before deciding whether to substitute them, though that period could be longer if the player were to leave the pitch.

There are concerns that would be too short a time to properly evaluate the player and it is understood such considerations have meant the Premier League and Football Association are reluctant to commit to implementing the protocol immediately after it is agreed.

The recruitment of a specialist concussion team could be one of the solutions, according to the Ifab secretary, Lukas Brud. Before the protocols can be implemented, logistical and legal frameworks need to be put in place, amendments to the regulations need to be agreed then approved, he said, describing the hurdles to clear before trials can begin.

We are not encouraging the introduction mid-season, only allowing it. It will be down to individual competitions. Will it require a concussion team, a neurologist on hand? These are the questions competitions will ask and they will be required to feed back on challenges.

The announcement of the PFAs neurodegenerative disease working group will also bring extra focus on the plight of former players and their families with these conditions.

After receiving criticism over a perceived lack of support for members with dementia, including from Stiless son John, the players union said the group would help guide the PFA with decisions regarding the support and protection of former and current footballers.

Previously our support has predominantly been based on financial assistance and advice, it said. Now, with the guidance of our working group, we want to ensure a more holistic support system is available for former footballers and their families.

In another development lawyers have called for former players to come forward with their stories before potential legal action. The personal injury specialists John Foy and James Byrne, alongside Nick De Marco QC, are representing a group of players and hope to establish whether clubs and governing bodies have taken timely and proper steps to prevent the injuries we are seeing, according to De Marco.

The litigation is still in its early stages and we still want to hear from professional sports players, De Marco said. By bringing this case we hope not only to provide our clients with adequate compensation to pay for the future medical treatment and care they will inevitably need but also to bring about much-needed reform.

Read the original post:
Clubs may need to hire neurologists as part of plans to combat concussion - The Guardian

New NIH BRAIN Initiative awards move toward solving brain disorders – National Institutes of Health

News Release

Thursday, November 19, 2020

Researchers using recently developed tools to gain new insights into brain function.

The National Institutes of Health will fund more than 175 grants, totaling nearly $500 million, through the NIHs Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, part of a large effort among federal and non-federal partners to use knowledge about how the brain works to develop more effective therapies for neurological disorders.

Recent discoveries and new technologies supported by the BRAIN Initiative provide a solid foundation for the next phase of the program, which will focus on large transformative projects and lay the foundation for novel interventions for human brain disorders, said John Ngai, Ph.D., director of the NIH BRAIN Initiative. We are moving closer to a complete list of all of the components in the brain and learning how those parts work together. That knowledge will enable us to develop better treatments for neurologic and neuropsychiatric diseases.

The researchers represent a variety of scientific disciplines from chemistry to engineering to psychology and more.

The new awards include efforts to use deep brain stimulation to enhance sleep in people with Parkinsons disease; explore the neural circuits behind pain; employ ultrasound technology to precisely deliver drugs to the brain; and help people with acute spinal cord injury recover movements and bladder control.

Scientists are also making significant advances in human brain imaging by developing a new type of MRI scanner to watch the brain in action as someone moves; generating ultra-high resolution images of brain chemistry using new PET technology; and using ultrasound to noninvasively map brain electrical activity.

Some grants support integrated research on neuroethical implications of BRAIN-funded neuroscience projects, including issues concerning certain types of neurosurgery and ethical challenges of using mobile neuroimaging technology in field studies.

Meanwhile, others will take a unique approach to studying the brain by developing a range of innovative model systems, beyond traditional fruit flies and rodents. For example, they will study the circuits behind the way an octopus sees and makes decisions; how moths detect harmful stimuli; and the brain connections bats use to navigate in the dark. These studies will provide insights into ways that brain circuitry can affect human behavior.

The BRAIN Initiative started in 2013 as a large-scale effort to accelerate neuroscience research by providing researchers with tools to study and treat human brain disorders. The NIH BRAIN Initiative has focused on brain circuit structure and function as well as the development of technologies to manipulate connections. To date, more than 900 awards totaling approximately $1.8 billion have been supported by the NIH BRAIN Initiative, which is collaboratively managed by 10 institutes.

A number of BRAIN Initiative-supported research findings have been published over the past year including identification of neurons that help rats envision future scenarios; the discovery of specific cells activated by general anesthesia and that may be potential targets for chronic pain treatments; advances in imaging technology that can measure brain activity up to 3,000 times per second in animals; examining nonverbal behavior in people with severe depression who receive deep brain stimulation; watching as odor-sensing cells within the nose react to complex smells; finding brain cells that can initiate torpor, a state of inactivity similar to hibernation; and a new device that may allow real-time control of prosthetic limbs.

For more information, please visit:https://braininitiative.nih.gov/

The NIH BRAIN Initiative is managed by 10 institutes whose missions and current research portfolios complement the goals of the BRAIN Initiative: National Center for Complementary and Integrative Health, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and other Communication Disorders, National Institute of Mental Health, and National Institute of Neurological Disorders and Stroke.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

Continued here:
New NIH BRAIN Initiative awards move toward solving brain disorders - National Institutes of Health

Global Enteral Feeding Device Used for Neurology Market 2020 Top Manufactures, Growth Opportunities and Investment Feasibility 2025 – The Daily…

Global Enteral Feeding Device Used for Neurology Market 2020 by Manufacturers, Type and Application, Forecast to 2025 released by MarketsandResearch.biz is the most important research for those who look for complete and authenticate information on the Enteral Feeding Device Used for Neurology market. The report compiles data on market size, market growth trends that will help its buyer to capture opportunities, to know and minimize probable risks, as well as to analyze the strategies of key companies in the market. The report offers a detailed assessment of the market to understand the current trend of the market and figure outs the expected market trend for the market for the forecast period from 2020 to 2025. Then, an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production have been highlighted in the report.

Competitive Landscape:

The in-depth analysis of the industrial chain supporting the Enteral Feeding Device Used for Neurology market in the globe incorporates factual information about every aspect of the market such as information about manufacturers profiles, sales volume, price, gross margin, the contribution to the global industry in terms of revenue. The degree of competition among leading global companies has been elaborated by examining various leading key players operating across the global regions. The leading manufacturers have been analyzed by using research methodologies for getting insight views on global competition. The data related to each of the companies has been presented from historic years and is projected forecast period.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/103551

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

In the global Enteral Feeding Device Used for Neurology market, the following companies are covered: Fresenius Kabi, Moog, Nestle, Danone, Abbott, Cardinal Health, Cook Medical, B. Braun, Avanos Medical, Applied Medical Technology, Alcor Scientific, Boston Scientific, BARD, Vygon, ConMed

On the basis of product types, the market report offers insight into major adoption trends for the following segments: , Enteral Feeding Pumps, Enteral Feeding Tubes, Consumables

Market segment by applications considering consumption growth rate and market share: , Hospitals, Home Care

The research offers an analysis of the geographical landscape of the global Enteral Feeding Device Used for Neurology market, which is divided into regions such as: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

The report has added comprehensive segmentation with respect to the component, functionality, end-user, and geography. Research and development activities and new product development and other trending factors are highlighted. It also aims to forecast the volume and value of the market in terms of key regions and countries. The restraints that are posing a threat to the global Enteral Feeding Device Used for Neurology market are further listed. From raw materials to end-users of this global Enteral Feeding Device Used for Neurology industry are analyzed.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/103551/global-enteral-feeding-device-used-for-neurology-market-2020-by-manufacturers-type-and-application-forecast-to-2025

Why Should You Buy This Report?

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Other Related Reports:

Global Ophthalmic Diagnostic Equipment Market 2020 Key Business Strategies, Technology Innovation and Regional Data Analysis to 2026

Global Industrial Fork Lift Trucks Market 2020 Competitive Dynamics, Growth Analysis, Segmentation and Worldwide Players Strategies up to 2026

Global Flight Support Systems Market 2020 Key Stakeholders, Growth Opportunities, Value Chain and Sales Channels Analysis 2026

Global Sorafenib Market 2020 Key Drivers and Restraints, Regional Outlook, End-User Applicants by 2026

Global Para Tertiary Butyl Phenol Market 2020 Segmented by Product, Application, Key Players and Regional Analysis to 2026

Originally posted here:
Global Enteral Feeding Device Used for Neurology Market 2020 Top Manufactures, Growth Opportunities and Investment Feasibility 2025 - The Daily...

8 foods and drinks that are common migraine triggers, according to a neurologist – Insider – INSIDER

Have you ever wondered if that glass of red wine with dinner might have triggered the pounding headache you felt later that night? The answer might be yes.

"Several studies show a link between food and beverages and migraines," says Thomas Berk, MD, neurologist and headache specialist at NYU Langone Health and Assistant Professor of Neurology at NYU Grossman School of Medicine.

Migraine affects over one billion people worldwide, and 39 million in the US alone. Learn more about the disease, including the most common foods that can trigger a migraine.

The difference between headaches and migraines is largely to do with the severity of the pain.

A headache can be uncomfortable and last for hours to days. Whereas a migraine is considered to be a neurological disease and the most debilitating type of headache, with more than 90% of sufferers incapable of working or doing normal activities during a migraine attack.

"A headache is any kind of pain in the head or face, and there are over 120 different kinds of headaches, which include migraines," says Berk.

A migraine generally includes severe throbbing pain, typically on one side of the head, and it can last from four to 72 hours. Additional symptoms may include sensitivity to light, sound, and smell, nausea, vomiting, and a visual disturbance known as an aura.

"There is no universal food or beverage that triggers migraines," says Berk. Everyone predisposed to migraines has different triggers, some of which may be food or drink-related. Whatever the trigger may be, all migraine triggers affect the brain in the same way by lowering the threshold to migraines.

Here's an example of what could happen. You drink a glass of wine, which is a migraine trigger for you. That drink leads to the creation of inflammatory neurotransmitters that are produced in the brain. Those neurotransmitters make the blood vessels around the brain dilate, and the nerve endings send signals back to the brain to feel symptoms such as pain, sensitivity to light, nausea, and more.

Based on Berk's research and discussions with patients, here is his list of the eight most common foods, drinks, and food-related triggers for migraine headaches:

"Migraine disease is complex and affected by many factors," says Simy Parikh, MD, program director of Thomas Jefferson University's Post-Graduate Certificate Program in Advanced Headache Diagnosis and Management and Assistant Professor in the Department of Neurology at Thomas Jefferson University.

Here Parikh offers some steps you can take to potentially reduce migraine triggers:

Eat healthily and consistently. You may have noticed that the migraine trigger list was lacking a few major food groups "healthy" foods such as fruits, vegetables, and protein, in particular. A 2020 review showed that most "migraine-friendly" healthy eating plans, such as low-fat diets, provided a decrease in the frequency of migraine attacks.

In addition to eating healthy foods, it's important to keep a consistent eating schedule to avoid migraines.

"Low blood glucose can trigger headaches," says Parikh. To keep your blood sugar steady, eat at roughly the same time every day without an extended amount of time between meals, she says. Parikh also suggests to all of her patients to maintain a healthy diet and weight.

Track food triggers and eliminate them from your diet. Since multiple factors contribute to migraines, many sufferers keep a headache diary. This is where they can list the frequency, duration, and intensity of migraines, as well as possible triggers, including food and drink.

If a food, beverage, or additive is identified as a possible trigger, Parikh suggests avoiding it for a month to see what happens. It's important to eliminate only one potential exposure each month, otherwise, you won't be certain what is triggering an attack.

Tracking the impact of a dietary change can help distinguish actual food triggers from migraine-associated food cravings. It's also important to work with a doctor when making any diet changes, says Parikh.

Get your sleep. Sleep and migraine are closely linked. A 2020 review showed the two-way relationship between sleep disorders and migraines. In other words, poor sleep quality is a trigger for migraines, and migraine sufferers are also at an increased risk of sleep disorders. To reduce the risk of sleep as a trigger for migraines, Parikh recommends that her patients stick to a specific sleep schedule.

Reduce stress. Stress can also trigger migraines. In fact, in one study, four out of every five people with migraines reported stress as a trigger. Here are some ways to reduce stress:

Certain foods, drinks, and additives may trigger migraines, and tracking them in a headache diary with one elimination per month may be helpful. Getting good quality sleep, exercise, and reducing stress can also reduce migraine attacks.

Migraines can be brutally painful and life-altering. The causes of migraines are complex and not always known. However, research has shown that there are ways to potentially lessen the frequency, duration, and intensity of attacks.

Parikh emphasizes that it's important to support migraine sufferers and not blame them for trigger exposures that may provoke migraine attacks. "There are many factors that come together to cause migraines, and you can do everything 'right' and still get them," she says.

Go here to see the original:
8 foods and drinks that are common migraine triggers, according to a neurologist - Insider - INSIDER

Neurovascular Devices/Interventional Neurology Market Forecast to 2028: How it is Going to Impact on Global Industry to Grow in Near Future -…

Neurovascular Devices/Interventional Neurology Market 2020: Latest Analysis:

The most recent Neurovascular Devices/Interventional Neurology Market Research study includes some significant activities of the current market size for the worldwide Neurovascular Devices/Interventional Neurology market. It presents a point by point analysis dependent on the exhaustive research of the market elements like market size, development situation, potential opportunities, and operation landscape and trend analysis. This report centers around the Neurovascular Devices/Interventional Neurology-business status, presents volume and worth, key market, product type, consumers, regions, and key players.

Sample Copy of This Report @ https://www.quincemarketinsights.com/request-sample-59263?utm_source=Technoweekly/komal

The prominent players covered in this report: Stryker Corporation , Medtronic plc, Johnson & Johnson, Terumo Corporation, Penumbra, Inc., Abbott Laboratories, Merit Medical Systems, Inc., W. L. Gore & Associates, Inc., MicroPort Scientific Corporation.

The market is segmented into By Product (Embolic Coils, Stents, Neurothrombectomy Devices, Microcatheters, Balloon Occlusion Devices, Flow Diversion Devices, Clot Retrievers),By Pathology (Aneurysm, AVM).

Geographical segments are North America, Europe, Asia Pacific, Middle East & Africa, and South America.

It has a wide-ranging analysis of the impact of these advancements on the markets future growth, wide-ranging analysis of these extensions on the markets future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-59263?utm_source=Technoweekly/komal

This is anticipated to drive the Global Neurovascular Devices/Interventional Neurology Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Neurovascular Devices/Interventional Neurology Market are currently adopting new technological trends in the market.

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Neurovascular Devices/Interventional Neurology Market. The feasibility of the new report is also measured in this research report.

Reasons for buying this report:

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-59263?utm_source=Technoweekly/komal

About Us:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact Us:

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Here is the original post:
Neurovascular Devices/Interventional Neurology Market Forecast to 2028: How it is Going to Impact on Global Industry to Grow in Near Future -...

Worldwide Anti-Aging Market to 2030 – Industry Analysis and Growth Forecast – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Anti-Aging Market Research Report: By Product, Treatment, Demography - Global Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

The major driving factors for the anti-aging market are the rising number of awareness-raising seminars and conferences, surging geriatric population, increasing disposable income, technological advancements, expanding medical tourism sector, and escalating cosmetic surgery volume.

These factors will lead to an increase in the industry revenue from $191.5 billion in 2019 to $421.4 billion in 2030, at an 8.1% CAGR during 2020-2030 (forecast period). Products used to diminish the signs of aging are easily available at physical stores and online portals.

A key factor aiding the anti-aging market advance is the rising number of seminars and conferences being organized to make plastic surgeons, students, and the general public about the advanced anti-aging treatments. For instance, the Aesthetic & Anti-Aging Medicine World Congress (AMWC) hosted by EuroMediCom (Informa Group) in April 2019 in Monte Carlo, Monaco, included five knowledge sharing and discussion sessions on anti-aging and aesthetics. Formerly, the Aesthetic & Anti-Aging Medicine World Congress 13th Edition was hosted in Thailand in September 2018 by the American Academy of Anti-Aging Medicine (A4M).

Another major reason the demand for anti-aging treatments and products is increasing is the booming geriatric population. The United Nations says that the number of people in the age group of 65 and above will surge from 703 million in 2019 to 1.5 billion by 2050. With age, people experience stem cell and fibrous tissue loss, which leads to dryness, wrinkles, sagging, and pigmentary alteration. Therefore, in order to continue looking young and attractive, the geriatric population regularly uses anti-aging remedies, which tighten and revitalize the skin, in addition to making people look young.

North America is the dominant region in the anti-aging market currently, owing to the rising plastic surgery volume and geriatric population. The UN expects the number of elderly people on the continent to increase to 96.2 million by 2050 from 59.9 million in 2019. This, coupled with the growing volume of plastic surgeries, is expected to result in a massive surge in the demand for various therapies and products that help people look young and aesthetically appealing.

Market Dynamics

Trends

Drivers

Restraints

Opportunities

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/rpts2n

Read this article:
Worldwide Anti-Aging Market to 2030 - Industry Analysis and Growth Forecast - ResearchAndMarkets.com - Business Wire

Chair Professor in Medicine job with ZHEJIANG UNIVERSITY | 234472 – Times Higher Education (THE)

About Zhejiang University

Located in the historical and picturesque city of Hangzhou, Zhejiang University is a prestigious institution of higher education with a long history. Qiushi Academy, the predecessor of Zhejiang University, was founded in 1897 and was one of the earliest modern academies of higher learning established in China.

Zhejiang University focuses on assiduous study and research, and science and technological innovation. It has launched a number of international high-end academic platforms and gathered masters, scholars and high-level research teams in various disciplines. In recent years, Zhejiang University maintains a leading position in China in output indicators including publications, patents and etc., and has made abundant important achievements in science, technology, humanities and social sciences. Zhejiang University always takes initiative in catering for national and regional needs, and exerts itself to become an influential high-level source of innovation and a pool of talents.

About International School of Medicine

International School of Medicine, Zhejiang University (hereinafter referred to as the School, ZJU) is a higher medical education institute jointly supported by Zhejiang University and Yiwu government, located in the energetic city Yiwu. Underpinned by R&D driven force of International Research Institutes of Health Medicine, ZJU (the Institute), clinical resources of the 4th Affiliated Hospital, ZJU School of Medicine (ZJU4H) and medical education of International School of Medicine, the 3 in 1 institution, is creating a stimulating, world-class hub for medical education, research and clinical health care with the commitment in empowering future physician scientists, biomedical pioneers and medical leaders to succeed in medical challenges worldwide. It is dedicated in working across disciplines to expand the frontiers of scientific understanding, while converting the most promising breakthroughs into tangible health, to enlarge the scope of medical education and training the future medical leaders and pioneers, to achieve a shared development in future medicine, as well as to advance health and to build a shared future for mankind locally, regionally, nationally and globally.

International School of Medicine, ZJU invites talents in all branches of cutting-edge science and technology around the world. Areas of interest include, but are not limited to, Global Health, Oncology, Reproductive Medicine, Regenerative Medicine, Anti-Aging Medicine General Practice and Digital Medicine. Global talents are welcomed to join a vibrant scientific environment aiming at pressing medical challenges with core technologies in critical areas and conducting interdisciplinary research to address high-priority projects in future medicine. Please come and join us for a better shared future.

HIGHLIGHTS OF THE SCHOOL:

I. POSITION AND REQUIREMENT

Chair Professor

Candidates should be an internationally active academic member with globally-recognized contributions. Qualified candidate will be appointed as Qiushi Chair Professors of ZJU.

II.WORKING AND LIVING CONDITIONS

International School of Medicine, ZJU upholds the Universitys tradition of valuing our faculty and are committed to promoting their career development. We continue to optimize the campus academic environment, implement support policies, and offer internationally competitive work and living facilities.

III. REQUIRED DOCUMENTS FOR APPLICATION

Please send the following application documents in PDF format with NAME+POSITION toighm@zju.edu.cn

Should you have question please feel free to contact us. Application will be reviewed upon receipt.

Contact:

Mr. LOU +86-0579-89935020Ms. WANG +86-0571-88208183

Address: No.1575 North Chouzhou Road, Yiwu City, Zhejiang Province, China

Follow this link:
Chair Professor in Medicine job with ZHEJIANG UNIVERSITY | 234472 - Times Higher Education (THE)

Gene experts claim they identified human genes that can protect against Covid-19 – CNBC

COVID-19 Coronavirus molecule, March 24, 2020.

CDC | API | Gamma-Rapho via Getty Images

A team of CRISPR scientists at the New York Genome Center, New York University and Icahn School of Medicine at Mount Sinai say they have identified the genes that can protect human cells against Covid-19, a disease that has infected over 40 million and led to 1 million deaths worldwide. The discovery comes after an eight-month screen of all 20,000 genes in the human genome led by Dr. Neville Sanjana at the New York Genome Center. Leading virologist at Mount Sinai, Dr. Benjamin tenOever, developed a series of human lung cell models for the coronavirus screening to better understand immune responses to the disease and co-authored the study.

Their study, published online last month by Cell, will appear in the scientific peer-reviewed journal's Jan. 7 print issue.

The goal was two-fold: to identify the genes that make human cells more resistant to SARS-CoV-2 virus; and test existing drugs on the market that may help stop the spread of the disease.

The breakthrough comes at a time when drug makers such as Pfizer, Oxford-AstraZeneca and Moderna are fast-forwarding vaccine and therapeutics to treat Covid-19. On Friday, Pfizer and BioNTech requested emergency authorization from the FDA for their Covid vaccine that contains genetic material called messenger RNA, which scientists expect provokes the immune system to fight the virus.

In order to better understand the complex relationships between host and virus genetic dependencies, the team used a broad range of analytical and experimental methods to validate their results. This integrative approach included genome editing, single-cell sequencing, confocal imaging and computational analyses of gene expression and proteomic datasets.

After intensive research the scientists and doctors claim they have found 30 genes that block the virus from infecting human cells including RAB7A, a gene that seems to regulate the ACE-2 receptor that the virus binds to and uses to enter the cell. The spike protein's first contact with a human cell is through ACE-2 receptor.

"Our findings confirmed what scientists believe to be true about ACE-2 receptor's role in infection; it holds the key to unlocking the virus," said Dr. tenOever. "It also revealed the virus needs a toolbox of components to infect human cells. Everything must be in alignment for the virus to enter human cells."

The team discovered that the top-ranked genes those whose loss reduces viral infection substantially clustered into a handful of protein complexes, including vacuolar ATPases, Retromer, Commander, Arp2/3, and PI3K. Many of these protein complexes are involved in trafficking proteins to and from the cell membrane.

"We were very pleased to see multiple genes within the same family as top-ranked hits in our genome-wide screen. This gave us a high degree of confidence that these protein families were crucial to the virus lifecycle, either for getting into human cells or successful viral replication," said Dr. Zharko Daniloski, a postdoctoral fellow in the Sanjana Lab and co-first author of the study.

Using proteomic data, they found that several of the top-ranked host genes directly interact with the virus's own proteins, highlighting their central role in the viral lifecycle. The team also analyzed common host genes required for other viral pathogens, such as Zika or H1N1 pandemic influenza.

The research team also identified drugs that are currently on the market for different diseases that they claim block the entry of Covid-19 into human cells by increasing cellular cholesterol. In particular, they found three drugs currently on the market were more than 100-fold more effective in stopping viral entry in human lung cells:

The other five drugs that were tested called PIK-111, Compound 19, SAR 405, Autophinib, ALLN -- are used in research but are not yet branded and used in clinical trials for existing diseases.

Our findings confirmed what scientists believe to be true about ACE-2 receptor's role in infection; it holds the key to unlocking the virus.

Their findings offer insight into novel therapies that may be effective in treating Covid-19 and reveal the underlying molecular targets of those therapies.

The bioengineers in New York were working on other projects with gene-editing technology from CRISPR but quickly pivoted to studying the coronavirus when it swept through the metropolitan area last March. "Seeing the tragic impact of Covid-19 here in New York and across the world, we felt that we could use the high-throughput CRISPR gene editing tools that we have applied to other diseases to understand what are the key human genes required by the SARS-CoV-2 virus," said Dr. Sanjana.

Dr. Neville Sanjana and his team at the New York Genome Center used CRISPR to identify the genes that can protect human cells against Covid-19.

New York Genome Center

As he explained, "current treatments for SARS-CoV-2 infection currently go after the virus itself, but this study offers a better understanding of how host genes influence viral entry and will enable new avenues for therapeutic discovery."

Previously, Dr. Sanjana has applied genome-wide CRISPR screens to identify the genetic drivers of diverse diseases, including drug resistance in melanoma, immunotherapy failure, lung cancer metastasis, innate immunity, inborn metabolic disorders and muscular dystrophy.

"The hope is that the data from this study which pinpoints required genes for SARS-CoV-2 infection could in the future work be combined with human genome sequencing data to identify individuals that might be either more susceptible or more resistant to COVID-19," Dr. Sanjana said.

The New York team is not the first to use CRISPR gene editing techniques to fight Covid-19. Other bioengineering groups at MIT and Stanford have been using CRISPR to develop ways to fight the SARS-CoV-2 and develop diagnostic tools for Covid-19.

The potential for using CRISPR to eliminate viruses has already generated some enthusiasm in the research community. Last year, for example, Excision BioTherapeuticslicenseda technology from Temple University that uses CRISPR, combined with antiretroviral therapy, to eliminate HIV, the virus that causes AIDS.

Read the original:
Gene experts claim they identified human genes that can protect against Covid-19 - CNBC

Botulinum Toxin Market Estimated to Experience a Hike in Growth by 2025 – The Daily Philadelphian

Global Botulinum Toxin Market: Snapshot

Botulinum toxin, known to the mankind as one of the most poisonous biological substances, is a neurotoxin produced by theClostridium botulinum bacteria.Clostridium botulinum, the gram-positive, anaerobic, spore-forming bacteria commonly found in water, soil, on plants, and the intestinal tracts of animals can be elaborated into eight exotoxins, all interfering with the process of neural transmission and causing muscle paralysis.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1196

From the earliest recorded uses of the toxin for the management ofstrabismus in humans to being approved for the treatment of a number of spasticity-related conditions, it has now started witnessing demand across nearly all important sub-specialties of the medicine sector. It was approved by the FDA in 2002 for the cosmetic application of decreasing glabeller forehead frown lines temporarily.

Ever since, botulinum toxins continue to play a key role in the management of a wide range of medical conditions, especially hemifacial spasm, focal dystonias and strabismus, several spastic movement disorders, hyperhidrosis, hypersalivation, headaches, and certain chronic diseases that only partially respond to medical treatments. The set of potential new indications treatable by botulinum toxins is expanding at a rapid pace.

Cosmetological applications, one of the most popular and profitable applications of botulinum toxins, include correction of creases, fine lines, and wrinkles over the face, neck, chin, and chest.Dermatological applicationsof the toxin, including hyperhidrosis, are also gaining increased popularity, chiefly as botulinum toxin injections are often well tolerated and lead to few side effects.

Global Botulinum Toxin Market: Overview

The international botulinum toxin (BNT) market is gigantically advantaged by the soaring number of applications for different purposes. A recent study has revealed that BNT can be used for benefitting patients with shoulder disorders such as those who undergo rotator cuff surgery. BNT in the form of onabotulinum toxin A (OnabotA) is licensed in several countries such as Korea to help with neurogenic detrusor overactivity (NDO) induced urinary incontinence attributable to multiple sclerosis or spinal cord injury.

The world BNT market could be segregated as per two key classifications, i.e. product type and end use. Maintaining a promising share in the global market, botulinum toxin type A (BNTA) is envisioned to be a faster growing product with applications in both aesthetic and therapeutic fronts.

The report on the global BNT market has been compiled after taking comprehensive efforts to gather vital insights for procuring future growth prospects, opportunities to rise against the odds, and data related to the current and future competitive scenario.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1196<ype=S

Global Botulinum Toxin Market: Trends and Opportunities

The aesthetic classification by type of end use is prognosticated to make a positive difference in the overall BNT market with a record share registered in 2015. BNT finds application in the treatment of glabellar lines, crows feet, and frown lines. As a result, it has received a significant demand in terms of primary cosmetic application for controlling aging signs and enhancing facial appearance.

Since BNT is a neurotoxin, the lackluster in the adoption of neurotoxins could raise questions on the demand in the global BNT market. The market growth could be further hindered with substandard reimbursement coverage on few products and extortionate treatment procedures. Moreover, shortness of breath and allergic reactions are some of the side effects witnessed on the part of neurotoxins.

However, a substantial number of BNT applications is expected to birth in the near future on account of large investments in research and development projects. The demand for BNT is anticipated to augment even more with the increase in demand for non-invasive and minimally invasive treatments. Vendors can also keep their hopes alive during any turmoil in the market with the escalation of geriatric population.

The therapeutic use of BNT is predicted to see a constant rise owing to the growing application of botulinum toxin B (BNTB) in the treatment of cervical dystonia and Xeomin and Dysport products for hyperhidrosis and blepharospasm.

Global Botulinum Toxin Market: Regional Outlook

Asia Pacific is analyzed to possess the potential to rise as a reliable geographical segment to bet the bottom dollar on. The demand in the Asia Pacific BNT market is envisaged to aggravate as players ride on the growing aged population and their need for anti-aging products. Besides augmenting disposable income, vendors in the Asia Pacific region could heavily benefit from the hot social awareness about commercial anti-aging products in countries such as Japan, China, and India.

Having won the crown of dominant growth in 2015, North America is expected to raise the growth bar once again on the back of the elevating BNT demand for improving external appearances and other aesthetic reasons.

Global Botulinum Toxin Market: Companies Mentioned

Considering their influence in the world BNT market on the basis of commercial availability and brand identity, companies such as Merz Pharma GmbH and Co. KgaA, Ipsen Group, Allergan, Inc., US Worldmeds, LLC, and Medytox, Inc. are predicted to top the list of best global players. These players are foreseen to take advantage of the colossal adoption of BNT on account of tangible benefits such as speedy healing of wounds, shorter stay in the hospital, and small incision.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1196

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read the original here:
Botulinum Toxin Market Estimated to Experience a Hike in Growth by 2025 - The Daily Philadelphian

Eluminex Biosciences, an Ophthalmology-Focused Biotechnology CompanyAnnounces Closing of $50 Million Series A Financing – BioSpace

Shanghai, China, Nov. 20, 2020 Eluminex Biosciences Limited (Eluminex), an ophthalmic biotechnology company committed to the discovery and development of first-in-class and/or best-in-class therapies, today announced the completion of a $50 million (USD) Series A Financing co-led by Lilly Asia Ventures, GL Ventures (venture capital arm of Hillhouse Capital), and Quan Capital. The Eluminex headquarters and research and development center are located in Suzhou Industrial Park; the business center is based in Shanghai, and future plans include establishing a global clinical and registration center in the San Francisco Bay Area.

We greatly appreciate the profound level of support and trust from three global investors, said Jinzhong Zhang, PhD, Co-Founder, Chairman, and Chief Executive Officer. With these proceeds, our goal is to build an innovative pipeline addressing critical unmet medical needs in vision-threatening diseases for patients worldwide. Additionally, we are pleased to have three world-renowned professors of ophthalmology as members of our Scientific Advisory Board: Quan Dong Nguyen, MD, MSc (Stanford University), Zuguo Liu, MD, PhD (Xiamen University), and Xiaodong Sun, MD, PhD (Shanghai Jiao Tong University). We are grateful for their significant contributions in helping us develop our pipeline programs.

The company also announced that Charles Semba, MD, has joined Eluminex as Chief Medical Officer (CMO). Dr. Semba is an internationally recognized leader in ophthalmic drug development. He has served as CMO in three prior ophthalmic companies: SARcode Bioscience (acquired by Shire/Takeda), ForSight VISION5 (acquired by Allergan), and Graybug Vision (NASDAQ: GRAY). He has held senior leadership roles as Vice President Ophthalmic Medicine at Shire/Takeda and Ophthalmology Group Head at Genentech. Dr. Semba led the clinical development of ranibizumab (LUCENTIS), the first global blockbuster anti-VEGF agent to reverse blindness in wet age-related macular degeneration and lifitegrast (XIIDRA), the first novel agent for the treatment of both signs and symptoms of dry eye disease; XIIDRA was acquired by Novartis for over $5 billion (USD).

Regarding the success of this financing, all parties have expressed their confidence and expectations for the new company. Closing Series A financing is indeed a major milestone. The leadership at Eluminex should be congratulated for this impressive achievement amidst current global events. commented Dr. Nguyen, Professor of Ophthalmology at the Byers Eye Institute, Stanford University. Such financial success and security demonstrate the trusts that the company has earned from the investment community in Eluminexs research and development therapeutic plans to preserve and enhance vision for patients with devastating ocular diseases worldwide.

Driven by an aging population and overuse of eyes in various ages, the ophthalmic market is seeing huge unmet needs for new products. The teams solid track record and rich experience in ophthalmic drug development enables the company to develop innovative therapies not only for China but for the global market. We are thrilled and honored to join hands with this seasoned team and partner with reputable investors from the very beginning, said Stephen Lin, Partner at Lilly Asia Ventures.

The founding team of Eluminex Biosciences has rich experience in drug development and innovation with great potential in the future. Hillhouse will help Eluminex continue to innovate, research and develop leading ophthalmic disease treatment drugs, meeting the needs of a large number of patients, and continue to create social well-being," said Michael Yi, Partner and Co-Chief Investment Officer of Hillhouse Capital Group.

Quan Capital is committed to foster innovation and bring new solutions to patients with great unmet needs. We are pleased to co-lead the Series A round of Eluminex and are truly impressed by the stellar management team, said Marietta Wu, Managing Director of Quan Capital. We believe this team of seasoned industry veterans both globally and in China will build a leader in ophthalmology with accelerated development of novel therapeutics. Quan looks forward to working closely with the team and contributing our local resources and global networks.

_________________

About Eluminex Biosciences

Eluminex was established in February 2020 with the commitment to leading the development of novel therapeutics for the benefit of patients with vision-threatening eye diseases worldwide. Co-Founders, Dr. Jinzhong Zhang and Dr. Zhenze John Hu, have assembled a top tier management team with significant ophthalmic drug development experience, aiming to build a robust and sustainable innovative ophthalmic pipeline to tackle the unmet clinical needs. For detailed information contact Zhenze John Hu at john.hu@eluminexbio.com

About Lilly Ventures Asia

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm founded in 2008, with offices in Shanghai, Hong Kong, and Menlo Park. LAVs vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that can treat diseases and improve human health. For more information, visit http://www.lillyasiaventures.com.

Link:
Eluminex Biosciences, an Ophthalmology-Focused Biotechnology CompanyAnnounces Closing of $50 Million Series A Financing - BioSpace

Is BELLUS Health Inc (BLU) the Top Pick in the Biotechnology Industry? – InvestorsObserver

BELLUS Health Inc (BLU) is around the middle of the Biotechnology industry according to InvestorsObserver. BLU received an overall rating of 43, which means that it scores higher than 43 percent of all stocks. BELLUS Health Inc also achieved a score of 43 in the Biotechnology industry, putting it above 43 percent of Biotechnology stocks. Biotechnology is ranked 36 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

BELLUS Health Inc (BLU) stock is unchanged 0% while the S&P 500 is down -0.27% as of 1:21 PM on Friday, Nov 20. BLU is flat $0.00 from the previous closing price of $3.18 on volume of 1,380,191 shares. Over the past year the S&P 500 has gained 15.10% while BLU is down -53.10%. BLU lost -$0.60 per share the over the last 12 months.

Click Here to get the full Stock Score Report on BELLUS Health Inc (BLU) Stock.

Continued here:
Is BELLUS Health Inc (BLU) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Is Kazia Therapeutics Ltd (KZIA) The Right Choice in Biotechnology? – InvestorsObserver

The 60 rating InvestorsObserver gives to Kazia Therapeutics Ltd (KZIA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 76 percent of stocks in the Biotechnology industry, KZIAs 60 overall rating means the stock scores better than 60 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Kazia Therapeutics Ltd (KZIA) stock is trading at $11.12 as of 1:21 PM on Friday, Nov 20, a drop of -$0.88, or -7.33% from the previous closing price of $12.00. The stock has traded between $10.52 and $11.99 so far today. Volume today is 863,594 compared to average volume of 726,043.

Click Here to get the full Stock Score Report on Kazia Therapeutics Ltd (KZIA) Stock.

See the original post here:
Is Kazia Therapeutics Ltd (KZIA) The Right Choice in Biotechnology? - InvestorsObserver

Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021 -…

Promising Progress on Clinical Development Progress, Collaborations and Partnering

Mutually Ended Discussion on Medical Cannabis Commercial and Merger Agreements

TEL AVIV, Israel, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the third quarter ended September 30, 2020. Subsequent to the end of the third quarter, the Company announced several other key achievements subsequent to the end of the third quarter that position it for continued success in 2021, including clinical and operational objectives:

Initiated its clinical trial in the U.S. The trial is being performed at Washington University School of Medicine in St. Louis, Missouri, which is among the leading medical centers in the U.S. The Principal Investigator for the clinical trial is Zhifu Xiang, M.D., of Washington University. He is an Associate Professor in the Division of Oncology's Bone Marrow Transplantation & Leukemia Section in the Department of Medicine. John Dipersio M.D, Ph.D., will act as co-Principal Investigator for the study. He is the chief of the Division of Oncology in the Department of Medicine at Washington University.

Entered into a collaborative agreement with the Swedish XNK Therapeutics, enabling it to leverage Cellects technology in Natural Killer cell therapies. XNK is a clinical stage Swedish company working with the Karolinska Institute.

In spite of the COVID-19 challenges we expedited our clinical and business development activities as we successfully achieved several objectives, commented Dr. Shai Yarkoni, Chief Executive Officer. Specifically, we recently initiated our U.S. clinical trial and entered into a partnership with a clinical stage biotech company that will leverage our functional cell selection technology. I believe these results reflect our steadfast determination and success progressing our clinical trials, which also includes the trial in Israel, combined with the latest collaboration agreement with XNK Therapeutics gives us multiple shots on goal to maximize shareholder value. We believe, based on our internal evaluation and assessment, that each of these opportunities could potentially represent significant revenue streams in the coming years.

Story continues

Separately, Cellect and Canndoc Ltd. have mutually agreed to end previously announced commercial and merger discussions. The Company will continue to pursue a partner that can bring value to its shareholders and progress the development of the Companys platform technology.

The Company's cash and cash equivalents totaled $6.07 million as of September 30, 2020. The Company will use its resources to progress clinical and business development efforts to advance its functional cell selection technology. The Company has sufficient funds to operate in the next 15 months. Reference is made to Note 1. C (Going Concern) in the Interim Consolidated Financial Statements as of June 30th, 2020, which were filed as an exhibit to a Form 6-K dated August 12, 2020.

Third Quarter 2020 Financial Results:

Research and development (R&D) expenses for the third quarter of 2020 were $0.37 million, compared to $0.72 million in the third quarter of 2019. The decrease in the R&D expenses is primarily due to decrease in clinical activities as a result of the COVID-19.

General and administrative (G&A) expenses for the third quarter of 2020 were $0.36 million compared to $0.80 million in the third quarter of 2019. The decrease in G&A expenses was primarily due to the decrease in professional expenses.

Finance income for the third quarter of 2020 were $0.26 million, compared to finance income of $0.12 million in the third quarter of 2019. The change was primarily due to changes related to the fair value of the tradable and non-tradable warrants issued in a prior fundraising.

Net loss for the third quarter of 2020 was $0.47 million, or $0.001 per share compared to $1.40 million, or $0.006 per share in the third quarter of 2019.

* For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on September 30, 2020 (U.S. $1 = NIS 3.441).

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of cell based therapies.

The Company's technology is expected to provide researchers, clinical community, and pharma companies with the tools to rapidly isolate specific cells in quantity and quality allowing cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Companys ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.

ContactCellect Biotechnology Ltd. Eyal Leibovitz, Chief Financial Officerwww.cellect.co +972-9-974-1444

Or

EVC Group LLC Michael Polyviou(732) 933-2754mpolyviou@evcgroup.com

Cellect Biotechnology LtdConsolidated Statement of Operation

Convenience

translation

Nine monthsended

Nine months ended

Three months ended

September 30,

September 30,

September 30,

2020

2020

2019

2020

2019

Unaudited

Unaudited

U.S. dollars

NIS

(In thousands, except share and per share data)

Research and development expenses

1,218

4,190

9,551

1,289

2,465

General and administrative expenses

1,727

5,944

7,832

1,241

2,768

Operating loss

2,945

10,134

17,383

2,530

5,233

Financial expenses (income) due to warrants exercisable into shares

790

2,717

(8,020)

(1,090)

(910)

Other financial expenses, net

40

138

1,369

193

489

Total comprehensive loss

3,775

12,989

10,732

1,633

4,812

Loss per share:

Basic and diluted loss per share

0.010

0.036

0.051

0.004

0.021

Weighted average number of shares outstanding used to compute basic and diluted loss per share

390,949,079

390,949,079

208,771,303

390,949,079

224,087,799

Cellect Biotechnology Ltd.Consolidated Balance Sheet Data

Convenience

translation

September 30,

September 30,

December 31,

2020

2020

2019

Link:
Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021 -...

Is Liminal BioSciences Inc (LMNL) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

The 39 rating InvestorsObserver gives to Liminal BioSciences Inc (LMNL) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 36 percent of stocks in the Biotechnology industry, LMNLs 39 overall rating means the stock scores better than 39 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 39 means the stock is more attractive than 39 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Liminal BioSciences Inc (LMNL) stock is trading at $4.27 as of 10:54 AM on Wednesday, Nov 18, an increase of $0.40, or 10.24% from the previous closing price of $3.87. The stock has traded between $4.01 and $4.50 so far today. Volume today is high. So far 1,253,784 shares have traded compared to average volume of 521,225 shares.

Click Here to get the full Stock Score Report on Liminal BioSciences Inc (LMNL) Stock.

Excerpt from:
Is Liminal BioSciences Inc (LMNL) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Food Biotechnology market performance to bolster in the forecast period | ArcadiaBiosciences, Monsanto, AquaBountyTechnologies, Bayer CropScienceAG -…

A recently introduced Global Food Biotechnology Market report includes factors such as size, growth, share, industry trends and project its growth by 2026. This comprehensive study aims to provide an overview of with in-depth market breakdown by product type, application, end-user, and region and collect useful data for this extensive, commercial study of the Food Biotechnology market. Furthermore, in-depth competitive landscape, forecast, strategies import/export consumption, supply and demand figures, cost price and production value gross margins are also provided in the Food Biotechnology industry.

The TOP STANDING OUT COMPANIES profiled are:

ArcadiaBiosciencesMonsantoAquaBountyTechnologiesBayer CropScienceAGCamson Bio TechnologiesBASFPlantScienceHy-LineInternationalDowDuPontKWS GroupEvogeneLtdOrigin AgritechSyngenta AG

Get Sample PDF [emailprotected] https://www.reportsintellect.com/sample-request/1583730

The report highlights key growth strategies adopted by these players of the Food Biotechnology industry, including details such as financial overview, product/services offered, prominent developments, and value chain analysis. In the beginning of the report introduced the Food Biotechnology basics: definitions, classifications, applications and market overview. In the end, the report introduced new project SWOT analysis, investment feasibility and investment return analysis as well as the conclusion of the research study is provided.

Market Segmentation

Food Biotechnology Market by Type

Transgenic CropsSynthetic Biology Derived Products

Food Biotechnology Market by Application

AnimalsPlantsOther

Food Biotechnology Market by Geography

North America Country (United States, Canada)

South America

Asia Country (China, Japan, India, Korea)

Europe Country (Germany, UK, France, Italy)

Other Country (Middle East, Africa, GCC)

Major Points from Table of Contents:-

Chapter 1: Market Overview, Scope, Market risks, or systematic risks and Segment by Type, End-User & Major Regions Market Size

Chapter 2 analyses most eminent Players of the Food Biotechnology Market by sales, revenue etc for the Forecast period 2020 to 2026Chapter 3 Competitive landscape based on sales, revenue, volume, market share etc for the period 2020 to 2026.Chapter 4 illustrate the global market by regions and their market share, sales, revenue etc for the period to 2026.Chapters 5 to 9 analyse the Food Biotechnology regions with Food Biotechnology countries based on market share, revenue, sales etc.Chapter 10 and 11 contain the information concerning market basis types and application, sales market share, rate of growth etc for forecast period 2020 to 2026.Chapter 12 focuses on the market forecast for 2020 to 2026 for the Food Biotechnology Market by regions, type and application, sales and revenue, profit.Chapter 13 to 15 contain the transient details associate to sales channels, suppliers, traders, dealers, research findings and conclusion etc for the Food Biotechnology Market.

Get the discounted price for this report @ https://www.reportsintellect.com/discount-request/1583730

Questions Answered in the Food Biotechnology Market Report:

What You Can Expect From Our Report:

About Us:

Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to introduced the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.

So whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:[emailprotected]Phone No: + 1-706-996-2486US Address:225 Peachtree Street NE,Suite 400,Atlanta, GA 30303

Original post:
Food Biotechnology market performance to bolster in the forecast period | ArcadiaBiosciences, Monsanto, AquaBountyTechnologies, Bayer CropScienceAG -...

Agriculture Biotechnology Market to Witness Astonishing Growth by 2027 | ADAMA Agricultural Solutions, Vilmorin, Bayer and more – Cheshire Media

Agriculture Biotechnology Market with Covid-19 Impact Analysis: Forecast to Show Spurring Growth by 2020-2027 to its research database. The global Agriculture Biotechnology Market research report is an output of a brief assessment and an extensive analysis of practical data collected from the global Agriculture Biotechnology Market. The data are collected on the basis of industrial drifts and demands related to the services & products. The meticulously collected data offers for the process of effortless strategic planning. It also helps in creating promising business alternatives.

Free Sample Report + All Related Graphs & Charts @ https://www.statsandreports.com/request-sample/298355-global-agriculture-biotechnology-market-size-status-and-forecast-2019-2025

Asia-Pacific region is expected to dominate the market over the forecast period owing to the increasing focus on the research, development, and manufacturing of Agriculture Biotechnology in countries including China, Japan, India, and South Korea.

A perfect demonstration of the recent expansions and innovative technological resolutions offer our customers the liberty to develop their decision-making skills. This ultimately helps to work with perfect business alternatives and apply elegant implementations. The global Agriculture Biotechnology Market report emphasizes the latest developments, growth, new opportunities, and dormant tricks. It provides an all-inclusive stance of the global Agriculture Biotechnology Market. Requirement proportion and innovation of modern technologies are some of the key factors covered in the global Agriculture Biotechnology Market report.

Our Free Complimentary Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

This helps to understand the overall market and to recognize the growth opportunities in the global Agriculture Biotechnology Market. The report also includes a detailed profile and information of all the major market players currently active in the global Agriculture Biotechnology Market. The companies covered in the report can be evaluated on the basis of their latest developments, financial and business overview, product portfolio, key trends in the market, long-term and short-term business strategies by the companies in order to stay competitive in the market.

We are currently offering Quarter-end Discount to all our high potential clients and would really like you to avail the benefits and leverage your analysis based on our report.

Grab Your Report at an Impressive Discount (Use Corporate email ID to Get Higher Priority) @ https://www.statsandreports.com/check-discount/298355-global-agriculture-biotechnology-market-size-status-and-forecast-2019-2025

Some of the Major Market Player Profile Included in This Report is:

ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene, Certis, Dow AgroSciences, Eurofins, Evogene, Global Bio-chem Technology, Syngenta, KWS Saat, Marina Biotech, Monsanto

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Biochips, Deoxy ribonucleic acid (DNS) sequencing, Genome editing tools, Ribonucleic acid interference (RNAI), Synthetic biology.

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Transgenic crops market, Synthetic biology-enabled products market.

The greater part of the data gathered is presented in graphical form along with the related statistics. The global Agriculture Biotechnology Market report demonstrates the functioning of the main market players, suppliers, and dealers in detail. The report also highlights the restraints and drivers impacting the global Agriculture Biotechnology Market.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

The report analyzes various decisive constraints such as item price, production capability, profit & loss statistics, and transportation & delivery channels influencing the global Agriculture Biotechnology Market. It also covers the analysis of other important elements such as market demands, advancements, and product developments, various organizations, and processes impacting the global Agriculture Biotechnology Market. The global Agriculture Biotechnology Market research report emphasizes a variety of modifications done that improve the work process of the global Agriculture Biotechnology Market.

Get Customized Report in your Inbox within 24 hours at: https://www.statsandreports.com/enquiry-before/298355-global-agriculture-biotechnology-market-size-status-and-forecast-2019-2025

A methodically structured Agriculture Biotechnology Market research report is based on the primary and secondary resource. It portrays the data collected in a more communicative and expressive way allowing the customer to develop a well-structured plan to develop and expand their businesses in the estimated duration.

Promising Regions & Countries Mentioned in The Agriculture Biotechnology Market Report:

North America: United States, Canada, and Mexico. South & Central America: Argentina, Chile, and Brazil. Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa. Europe: UK, France, Italy, Germany, Spain, and Russia. Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Buy Full Copy Global Agriculture Biotechnology Report 2020-2027 @ https://www.statsandreports.com/placeorder?report=298355-global-agriculture-biotechnology-market-size-status-and-forecast-2019-2025&type=SingleUser

COVID-19- Current Scenario & Potential Impact

Various communities and companies are doing their best to function and perform, and eventually cope with the challenges raised by COVID-19 pandemic. The COVID-19 pandemic had a negative impact on the market size for the year 2020, with small and medium scale companies struggling to sustain their businesses in the near-term future. Industry leaders are now focusing to create new business practices to deal with crisis situations like COVID-19 pandemic.

The report presents a strategic analysis of the Agriculture Biotechnology market through key drivers, challenges, opportunities, and growth contributors. Further, the market attractiveness index is provided based on five forces analysis.

The Agriculture Biotechnology market delivers value to customers through reliable market size for 2019 on the basis of demand and price analysis. The report presents near term and long term forecast of the addressable Agriculture Biotechnology market size to 2027.

(We customize your report according to your research need. Ask our sales team for report customization. [emailprotected] )

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Us

Stats and Reports is a global market research and consulting service provider specialized in offering wide range of business solutions to their clients including market research reports, primary and secondary research, demand forecasting services, focus group analysis and other services. We understand that how data is important in todays competitive environment and thus, we have collaborated with industrys leading research providers who works continuously to meet the ever-growing demand for market research reports throughout the year.

Contact:

Stats and ReportsMangalam Chamber, Office No 16, Paud RoadSankalp Society, Kothrud, Pune, Maharashtra 411038Phone: +1 650-646-3808Email: [emailprotected]Website: https://www.statsandreports.comFollow Us on: LinkedIN | Twitter |

See more here:
Agriculture Biotechnology Market to Witness Astonishing Growth by 2027 | ADAMA Agricultural Solutions, Vilmorin, Bayer and more - Cheshire Media